Previous 10 | Next 10 |
Kuros Biosciences (OTCPK:CSBTF) said $2.5M of a $5M milestone payment due to Kuros will be paid to Xoma (NASDAQ:XOMA), as Checkmate Pharmaceuticals' acquisition was completed by Regeneron Pharmaceuticals. In July 2021, Xoma acquired a royalty interest position Kuros held, under a 20...
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules • $2.5 million of milestone to be paid to XOMA Corporation under royalty agreement SCHLIEREN (ZURICH), Switzerland, June 02, 2022 (GLOBE NEWSWIRE) -- Kuros Biosciences AG (“Kuros” ...
The recessionary risk, COVID-19 pandemic, and the war in Ukraine could force the global pharmaceutical industry to cut drug prices, Takeda (NYSE:TAK) Chief Executive Christophe Weber said in a letter to shareholders on Tuesday. Weber pointed out that government budgets have increasingly come ...
Regeneron Completes Acquisition of Checkmate Pharmaceuticals PR Newswire Acquisition strengthens Regeneron's innovative portfolio of immuno-oncology candidates and diversified approach to cancer treatment TARRYTOWN, N.Y. , May 31, 2022 /PRNewswire...
FDA Accepts Dupixent® (dupilumab) for Priority Review in Adults with Prurigo Nodularis PR Newswire TARRYTOWN, N.Y. and PARIS , May 31, 2022 /PRNewswire/ -- Dupixent would be the first and only medicine specifically indicated to treat prurigo no...
Citing data from 1995, Wells Fargo argues that for every half a percentage point increase in treasury yield, there is a 5.6% decrease in the average deal premium paid in biopharma acquisitions, a trend favoring large-cap pharma as the Fed hikes interest rates. Wells Fargo noted the relationsh...
Biotechnology giant Regeneron 's (NASDAQ: REGN) eye medication EYLEA is one of the best-selling blockbuster drugs around, generating $9.4 billion sales globally in 2021. The drug is approved for a number of eye diseases and has been a mainstay for Regeneron for the past decade. Alth...
Leerink has initiated Regeneron Pharmaceuticals (NASDAQ:REGN) with an outperform rating citing the company's strong sales of Dupixent (dupilumab) and Eylea (aflibercept). The firm has a $738 price target (~12% upside based on Friday's close). Analyst David Risinger said that he sees success f...
Regeneron Pharmaceuticals (NASDAQ:REGN) said a phase 3 trial of Evkeeza (evinacumab) met its main goal in children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH). HoFH is a rare inherited condition and is a type of of familial hypercholesterolemia — a disor...
Regeneron has a very strong pipeline consisting of treatments that can complement current cash cows (EYLEA and Dupixent) along with potential blockbusters. Even if EYLEA rapidly loses market share after its patent expirations, the growth from Dupixent and Libtayo will be more than eno...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...